PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.016

Abstract

Abstract: Glioblastoma multiforme(GBM)is one of the most common primary malignant brain tumors.GBM has the characteristics of high invasiveness,high recurrence rate and low survival rate,with a poor prognosis.Programmed cell death receptor 1(PD-1)/programmed cell death ligand 1(PD-L1)as the main immune checkpoint(IC),the formation of immune pathways can trigger negative regulation of immune response and enhance the invasiveness of GBM cells in brain tissue.Research into GBM treatment is ongoing,and immune checkpoint inhibitors(ICIs)have also received considerable attention.ICIs activate antitumor response by inhibiting negative immunoregulatory pathways,providing a new therapeutic approach for GBM.Several clinical studies have focused on the combination of standard therapy(temozolomide,radiotherapy),targeted therapy,and other immunotherapies.This review describes the PD-1/PD-L1 pathways,and summarizes the research progress of PD-1/PD-L1 monotherapy,neoadjuvant therapy and combined chemotherapy,radiotherapy,targeted therapy,hormones,etc.in the treatment of GBM.

Key words: Glioblastoma, Programmed death receptor-1, Immunotherapy

CLC Number:

R739.4

TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme[J]. Journal of Practical Oncology, 2022, 36(3): 278-282.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.03.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I3/278

References

1 Ostrom QT,Gittleman H,Truitt G,et al.CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015[J].Neuro Oncol,2018,20(suppl 4):1-86.
2 Jiang T,Mao Y,Ma W,et al.CGCG clinical practice guidelines for the management of adult diffuse gliomas[J].Cancer Lett,2016,375(2):263-273.
3 Li B,Chan HL,Chen P.Immune checkpoint inhibitors:basics and challenges[J].Curr Med Chem,2019,26(17):3009-3025.
4 Maghrouni A,Givari M,Jalili-Nik M,et al.Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme:Preclinical evidence and clinical interventions[J].Int Immunopharmacol,2021,93:107403.
5 Han Y,Liu D,Li L.PD-1/PD-L1 pathway:current researches in cancer[J].Am J Cancer Res,2020,10(3):727-742.
6 Jiang Y,Chen M,Nie H,et al.PD-1 and PD-L1 in cancer immunotherapy:clinical implications and future considerations[J].Hum Vaccin Immunother,2019,15(5):1111-1122.
7 Messenheimer DJ,Jensen SM,Afentoulis ME,et al.Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-ox40[J].Clin Cancer Res,2017,23(20):6165-6177.
8 Wang X,Guo G,Guan H,et al.Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma[J].J Exp Clin Cancer Res,2019,38(1):87.
9 Sun C,Mezzadra R,Schumacher TN.Regulation and function of the PD-L1 checkpoint[J].Immunity,2018,48(3):434-452.
10 Tang J,Yu JX,Hubbard-Lucey VM,et al.Trial watch:The clinical trial landscape for PD-1/PD-L1 immune checkpoint inhibitors[J].Nat Rev Drug Discov,2018,17(12):854-855.
11 Ott PA,Bang YJ,Piha-Paul SA,et al.T-cell-inflamed gene expression profile,programmed death ligand 1 expression,and tumor mutational burden predict efficacy in patients treated with pembrolizumab cross 20 cancers:KEYNOTE-028[J].J Clin Oncol,2019,37(4):318-327.
12 Kurz SC,Cabrera LP,Hastie D,et al.PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma[J].Neurology,2018,91(14):1355-1359.
13 Lukas RV,Rodon J,Becker K,et al.Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma[J].J Neuro Oncol,2018,140(2):317-328.
14 Yang T,Kong Z,Ma W.PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma:clinical studies,challenges and potential[J].Hum Vaccin Immunother,2021,17(2):546-553.
15 Berghoff AS,Kiesel B,Widhalm G,et al.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma[J].Neuro Oncol,2015,17(8):1064-1075.
16 Galon J,Bruni D.Approaches to treat immune hot,altered and cold tumours with combination immunotherapies[J].Nat Rev Drug Discov,2019,18(3):197-218.
17 Antonios JP,Soto H,Everson RG,et al.Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma[J].Neuro Oncol,2017,19(6):796-807.
18 Berghoff AS,Preusser M.Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?[J].Nat Rev Neurol,2019,15(6):314-315.
19 Schalper KA,Rodriguez-Ruiz ME,Diez-Valle R,et al.Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma[J].Nat Med,2019,25(3):470-476.
20 Cloughesy TF,Mochizuki AY,Orpilla JR,et al.Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma[J].Nat Med,2019,25:477-486.
21 Wang S,Yao F,Lu X,et al.Temozolomide promotes immune escape of GBM cells via upregulating PD-L1[J].Am J Cancer Res,2019,9(6):1161-1171.
22 Karachi A,Yang C,Dastmalchi F,et al.Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition[J].Neuro Oncol,2019,21(6):730-741.
23 Newcomb EW,Demaria S,Lukyanov Y,et al.The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas[J].Clin Cancer Res,2006,12:4730-4737.
24 Zeng J,See AP,Phallen J,et al.Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J].Int J Radiat Oncol Biol Phys,2013,86(2):343-349.
25 Diaz RJ,Ali S,Qadir MG,et al.The role of bevacizumab in the treatment of glioblastoma[J].J Neurooncol,2017,133(3):455-467.
26 Tamura R,Tanaka T,Ohara K,et al.Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab[J].Cancer Sci,2019,110(2):499-508.
27 Reardon DANL,Peters KB,Peters KB,et al.Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma patients[J].J Clin Oncol,2018,36:2006.
28 David Reardon TK,Dietrich J,Dietrich J,et al.Atim-12.Phase 2 study to evaluate the clinical efficacy and safety of Medi4736(Durvalumab)in patients with Bevacizumab-refractory recurrent glioblastoma[J].Neuro Oncol,2017,19(suppl 6):28.
29 Puzanov I,Diab A,Abdallah K,et al.Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group[J].J Immunother Cancer,2017,5(1):95.
30 Eigentler TK,Hassel JC,Berking C,et al.Diagnosis,monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J].Cancer Treat Rev,2016,45:7-18.
31 Iorgulescu JB,Gokhale PC,Speranza MC,et al.Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma[J].Clin Cancer Res,2021,27(1):276-287.

[1]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[2]	YI Xiaoqi, DENG Hongbin. Application progress of PD-1/PD-L1 inhibitors in neoadjuvant treatment of bladder cancer [J]. Journal of Practical Oncology, 2022, 36(2): 183-187.
[3]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[4]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[5]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[6]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[7]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[8]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[9]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[10]	WANG Mingming, CHEN Xiaopin. Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(2): 179-183.
[11]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.
[12]	ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy [J]. Journal of Practical Oncology, 2021, 35(1): 55-58.
[13]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[14]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[15]	LIU Chao, ZHENG Tongsen. Summary and reflection on the medical work of oncology during the outbreak of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 100-102.

Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments